Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Device Impact on the Efficacy of Serum Product Study

10. November 2026 aktualisiert von: ChinaNorm

The goal of this clinical trial is to learn whether combining a beauty device with the test product affects skin parameters in women troubled by wrinkles. It aims to evaluate the impact of the beauty device on the efficacy of the test product. The main questions it aims to answer are:

- Does the combination of the beauty device plus test product achieve better skin improvement compared with using the test product alone?

Researchers will compare beauty device + test product applied to one half of the face and one side of the neck against the test product alone applied to the contralateral half-face and neck, to see whether the beauty device enhances the efficacy of the test product.

Participants will:

  • Receive randomized split-face and split-neck treatment during the study
  • Attend 10 scheduled study visits
  • Undergo standardized image capture, clinical assessment and instrumental skin measurement

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

35

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Rekrutierung
        • Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072, Shanghai,
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

25 Jahre bis 55 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • 1. Chinese female with 25 - 55 years old.
  • 2. All skin types, 50% self-declare sensitive skin.
  • 3. Self- declare with concerns on facial wrinkle problems.
  • 4. The difference in clinical grading between the two sides of the face should be less than one point.
  • 5. Presenting with following certain degree skin qualities clinical grading by dermatologist: Skin radiance, brightness, global appearance of fine lines, elasticity, plumpness, skin firmness: 3≤grade≤6 (refer to 0-9 scale); Crow's feet wrinkles: 2≤ grade (Skin Aging Atlas); Underneath eye wrinkle: 2≤ grade (Skin Aging Atlas); Nasolabial folds:2 ≤ grade (Skin Aging Atlas); Ptosis of the lower part of the face 1≤grade (Skin Aging Atlas);
  • 6. Did not participate any clinical test or cosmetic product test on skin within 3 months.
  • 7. Did not participate any chemical/beauty procedures for previous 6 months.
  • 8. No disagreement of dermatologist because of other reasons that exclude the participation of the subject.
  • 9. Willing and able to participate as evidenced by signing of informed consent and photo release form.
  • 10. Must be willing to comply with all study protocol requirements.

Exclusion Criteria:

  • 1. Pregnant or breast-feeding woman or woman planning pregnancy during the study.
  • 2. Subject deprived of rights by a court or administrative order.
  • 3. Major subject to a guardianship order.
  • 4. Subject residing in a health or social care establishment.
  • 5. Patient in an emergency setting.
  • 6. Subject with a skin disease in the test areas as well as skin allergy (particularly e.g., acne, rosacea, eczema).
  • 7. Subject presenting a stable or progressive serious disease (per investigator's assessment).
  • 8. Immuno-compromised subject.
  • 9. Subject with history of allergy to cosmetic or personal care products or ingredients.
  • 10. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
  • 11. Subject regularly practicing aquatic or nautical sports.
  • 12. Subject regularly attending a sauna.
  • 13. Subject with physical highly sensitive constitution.
  • 14. Subject with cardiovascular or circulatory history.
  • 15. Subject with a history of skin cancer or malignant melanoma.
  • 16. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune- suppressants in the last 6 months before study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Arm 1

Randomly assigned half-face and half-neck receives the beauty device combined with the test product. The study includes short-term on-site application and long-term home-use regimen.

Short-term: 1.48 g test product applied on half-face & half-neck, massaged by beauty device for about 5 min 50 sec at study site. Long-term: Subjects follow standardized home skincare routine between visits. On-site visits: treatment side receives beauty device and test product.

Aktiver Komparator: Arm 2

Contralateral half-face and half-neck receives only the test product without the beauty device, as within-subject control. The same home skincare regimen is followed.

Short-term: 0.45 g test product manually applied on half-face by staff, no beauty device. Long-term: same full-face home skincare routine. On-site visits: only test product is applied on this control side without beauty device treatment.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Dermatologist clinical assessment of skin parameters using modified Griffiths 10-point scale
Zeitfenster: 2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.

A dermatologist evaluates skin parameters on the left and right half-face/half-neck separately. Assessments include skin tone, skin quality and wrinkle parameters graded on a 0-9 scale. Half-point (0.5) or incremental values (0.4/0.6) may be used. The rater is blinded to prior scores after baseline.

2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Stratum corneum hydration measured by Corneometer® CM 825
Zeitfenster: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit

Skin hydration is measured bilaterally on cheeks using Corneometer® CM 825 (capacitance method). The mean value of 3 consecutive valid readings is recorded; higher values indicate greater hydration.

Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
Transepidermal water loss (TEWL) measured by Vapometer
Zeitfenster: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit

TEWL is measured bilaterally on cheeks using Vapometer. One reading is taken per site. Unit: g/m²h; lower values indicate better skin barrier function.

Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
wrinkle analysis using Antera 3D
Zeitfenster: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4

Antera 3D generates 3D colour images of skin surface by analysing shadow and light reflection. Standard wrinkle photographs are captured and analysed.

Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
Skin texture analysis using VisioScan VC20
Zeitfenster: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

VisioScan VC20 (UV CCD imaging probe) captures skin images on bilateral cheeks and neck. Images are processed and analysed by SELS software to evaluate skin smoothness.

Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
3D facial imaging using Vectera-H2
Zeitfenster: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4

Handheld Vectera-H2 captures 180° stereophotogrammetric 3D facial images. Assessment endpoint: facial fullness.

Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
Facial imaging acquisition using VISIA®-CR (Canfield)
Zeitfenster: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Facial images are captured by trained staff with VISIA®-CR, equipped with multiple light sources (standard, cross-polarized, parallel polarized, oblique, UV). Images are taken from left, central and right views with subject wearing hairnet and eyes closed.

Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

23. September 2026

Primärer Abschluss (Tatsächlich)

10. November 2026

Studienabschluss (Geschätzt)

30. November 2026

Studienanmeldedaten

Zuerst eingereicht

10. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. November 2026

Zuerst gepostet (Tatsächlich)

16. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • C26005101

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren